Cough is prevalent in patients with progressive pulmonary fibrosis (PPF) and significantly affects their quality of life.

Scientists have made a key breakthrough in treating respiratory diseases by developing a new drug delivery system that ...

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase ...

Pulmonary fibrosis encompasses a spectrum of interstitial lung diseases (ILDs) characterized by chronic inflammation, aberrant tissue remodeling, and ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype ...

Patients with pulmonary fibrosis (PF) and pulmonary hypertension (PH) have superior transplant-free survival outcomes if they receive pulmonary vasodilator therapy in combination with antifibrotic ...

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis. Forced oscillation technique (FOT) may be a useful tool to predict the course of ...

A promising new treatment approach for idiopathic pulmonary fibrosis (IPF), a fatal and currently untreatable lung disease affecting over 3 million people globally, has been identified by Tulane ...

Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, can potentially treat pulmonary fibrosis. Studies suggest it might ...

Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with progressive pulmonary fibrosis in a Phase 3 study, according to ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as Jose Herazo-Maya, MD, knows all too well, it is ...